MS HB565

Requires all health benefit plans, Medicaid, and the State and School Employees Health Insurance Plan to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases when supported by medical evidence, effective July 1, 2026

Biomarker testing includes analysis of tissue, blood, or biospecimens for gene mutations, protein expression, and genomic sequencing, with coverage required when supported by FDA approvals, CMS determinations, or nationally recognized clinical practice guidelines

Health insurers must update and publicly post medical policies within 60 days of enactment, and provide 30 days advance notice of any future policy changes affecting biomarker testing coverage

Insurers denying biomarker testing claims must provide specific written justification explaining the denial as it pertains to the individual patient, and must offer a clear appeals process accessible on their website

The act is named the "Jill Gary Eure Act" or "Jill's Law" and authorizes the Department of Insurance to conduct audits ensuring compliance with these coverage requirements